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Abstract
Background: Natalizumab (NTZ) discontinuation leads to multiple sclerosis reactivation.
The objective of this study is to compare disease activity in MS patients who continued on NTZ treatment to those
who were switched to subcutaneous interferon 1b (IFNB) treatment.
Methods: 1-year randomized, rater-blinded, parallel-group, pilot study (ClinicalTrial.gov ID: NCT01144052). Relapsing
remitting MS patients on NTZ for ≥12 months who had been free of disease activity on this therapy (no relapses
and disability progression for ≥6 months, no gadolinium-enhancing lesions on baseline MRI) were randomized to
NTZ or IFNB. Primary endpoint was time to first on-study relapse. Additional clinical, MRI and safety parameters
were assessed. Analysis was based on intention to treat.
Results: 19 patients (NTZ n=10; IFNB n=9) with similar baseline characteristics were included. 78% of IFNB treated
patients remained relapse free (NTZ group: 100%), and 25% remained free of new T2 lesions (NTZ group: 62.5%).
While time to first on-study relapse was not significantly different between groups (p=0.125), many secondary
clinical and radiological endpoints (number of relapses, proportion of relapse free patients, number of new T2
lesions) showed a trend, or were significant (new T2 lesions at month 6) in favoring NTZ.
Conclusions: De-escalation therapy from NTZ to IFNB over 1 year was associated with some clinical and
radiological disease recurrence. Overall no major safety concerns were observed.
Keywords: Multiple sclerosis, Natalizumab, Interferon beta1b, De-escalation, Progressive multifocal
leukoencephalopathy
Background
Natalizumab (NTZ) is an effective treatment for relapsing-
remitting multiple sclerosis (RRMS), but is associated with
an increased risk of progressive multifocal leucoencepha-
lopathy (PML) in JC virus (JCV) sero-positive patients in
function of treatment duration and pre-exposure to immu-
nosuppressants [1]. Based on current risk benefit assess-
ment [1], many physicians consider stopping treatment
after 1–2 years. Mean half-life of unbound NTZ after re-
peated administrations is 11 days, and the drug is fully
cleaned from the circulation within approximately 2
months after last infusion [2]. NTZ cessation may be
followed by recurrence of disease activity peaking 4–7
months later in a significant number of patients, predom-
inantly at MRI level [3,4]. Data providing guidance on the
management of these patients, who generally suffer from
rapidly evolving MS, are scarce. It had been suggested that
if alternate treatment could minimize the risk of clinical
flares, then NTZ dosage interruption might be an option
for PML prevention [5].
The objective of this pilot study was to generate initial
prospective data and hypotheses on the concept of de-
escalating NTZ-treated patients with RRMS to inter-
feron beta-1b (IFNB).
* Correspondence: chiara.zecca@eoc.ch
1Neurocenter of Southern Switzerland, Ospedale Regionale di Lugano,
Lugano, Switzerland
Full list of author information is available at the end of the article
© 2013 Gobbi et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Gobbi et al. BMC Neurology 2013, 13:101
http://www.biomedcentral.com/1471-2377/13/101Methods
This is a 1-year, prospective, controlled, randomized, rater
blinded, parallel-group, monocentric pilot study (Clinical
Trial.gov ID: NCT01144052). Included patients were fe-
males or males with RR-MS according to 2005
McDonald’s criteria, aged between 18 and 60 years, who
were on NTZ and feared or were at significant risk for
PML. Risk for PML was defined significant in case of
NTZ treatment duration equal to or greater than 12
months. Patients had to be free of disease activity while
on NTZ (free from relapses and disability progression
for at least 6 months and no gadolinium enhancing le-
sions [Gd+L] on baseline [BL] MRI). Main exclusion
criteria were pregnancy and breastfeeding; relevant
neurologic, internistic or psychiatric disorders; treatment
with steroids less than 1 month before study entry;
treatment with any immunomodulators or immu-
nosuppressors other than steroids, ACTH or NTZ in
the past year; inability to provide consent or comply
with study procedures, current participation to other
clinical trials. All the patients fulfilling inclusion and
exclusion criteria and treated at our center were contacted
and offered to participate.
Included patients were randomly assigned in a 1:1 ratio
to continue monthly intravenous NTZ 300 mg or to
de-escalate to every other day subcutaneous (s.c.) INFB
250 ug. INFB was started within 30 days after the last
NTZ infusion. Patients intolerant to INFB were allowed
to switch to daily s.c. glatiramer acetate (GA) 20 mg
(rescue therapy).
Primary endpoint was time to first on-study relapse
from randomization. Secondary endpoints included num-
ber of relapses, proportion of relapse free patients, severity
of relapses (severe relapse was defined by ≥1.5 increase in
EDSS score), 3 months confirmed disability progression
(defined by ≥1.0 increase in EDSS score), number of new
T2-hyperintense lesions (nT2L) and Gd+L per patient at
months 3, 6, 9 and 12.
EDSS and relapses assessment was performed by an
examining neurologist blinded to treatment. A relapse was
defined according to widely accepted international diag-
nostic and therapeutic guidelines [6] as newly developing
neurological symptoms or reactivation of pre-existing
neurological deficits for a minimum of 24 hours in the
absence of an increase in body temperature or infections
occurring at least 30 days after the preceding episode.
Relapses were confirmed when an increase of at least 1
point in at least one functional system was recorded.
The occurrence of fatigue, mental symptoms, and/or
vegetative symptoms without any additional signs was
not classified as a relapse.
MRI disease activity was assessed via subtraction MRI
(sMRI) [7] and via count of Gd+L by an expert who was
blinded to clinical data.
Safety monitoring included physical examination, regis-
tration of adverse events, laboratory analysis and quarterly
brain MRI.
Patients were consecutively recruited at the Neurocenter
of Southern Switzerland, from 2010 to 2011. A monito-
ring agency prepared the randomization list and provided
sealed envelopes for treatment allocation.
The study protocol is in compliance with the Helsinki
Declaration and was approved by the local ethics commit-
tee and Swissmedic. Patients provided written informed
consent before study enrollment. Written informed con-
sent was obtained from the patient for the publication of
this report and any accompanying images.
Statistical analyses were performed using non-parametric
tests for continuous variables and ordinal scores, and con-
s i d e r e ds i g n i f i c a n ta tt h el e v e lα=0.05. Analysis was based
on intention to treat. This pilot study was conducted to
generate first data and hypotheses for the planning of
further clinical trials. The sample size was set to 20 pa-
tients, i.e. 10 patients per group and was based on clinical
and practical considerations.
Results
Clinical findings
A total of 39 patients were screened, 25 fulfilled the inclu-
sion and exclusion criteria and were offered to participate.
Six patients refused their consent, 19 patients were in-
cluded (NTZ n=10; IFNB n=9). No significant differences
between treatment arms for baseline characteristics, in-
cluding annualized relapse rate (ARR) during the 2 years
prior to the NTZ run-in period, duration of run-in period
of NTZ treatment and EDSS at randomization, were
found (Table 1).
17/19 patients completed the study: one IFNB-patient
withdrew consent (day 34) because she could not comply
with study procedures; one NTZ-patient opted for an oral
treatment (day 139). One IFNB-patient (#9) switched to
rescue treatment at day 69 due to systemic side effects.
Median time to first on-study relapse was 103 days in
the IFNB group; no relapses were observed in the NTZ
group (p=0.125) (Table 2). Seven out of 9 (78%) IFNB-
patients remained relapse free, compared to all 10 in the
NTZ group (p=0.206) over the 1-year follow-up. Two
IFNB-patients experienced a total of 3 relapses (p=0.447),
all with transitory EDSS worsening [0.5 points in patient #5
and #14 (both at month 4), 1.5 points in patient #14
(month 11)]. Both patients scored negative for neutraliz-
ing antibodies against IFNB. No patient experienced
sustained disability progression. The ARR on study in
both treatment groups was significantly lower compared
to the period prior the run-in NTZ treatment (IFNB:
p=0.034; NTZ: p=0.005).
Injection site reactions occurred in 44% of IFNB-patients.
The median number of infections per patient was not
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p=0.140) (Table 2). There were no case of immune recon-
stitution inflammatory syndrome.
MRI findings
A higher number of nT2L was detected in the IFNB vs. the
NTZ group at each time point (Figure 1), this difference
being significant only for time point month 6 (Table 2).
However, the overall likelihood to remain free of nT2L was
significantly higher with NTZ (62.5%) than with IFNB therapy
(25%) (Figure 2). The number of Gd+L per patient did not
significantly differ between groups at any time point (Table 2).
No associations were found between ARR, nT2L and
Gd+L during the study period and demographic or clinical
parameters shown in Table 1.
Discussion and conclusions
We reported the effects on clinical disease activity and MRI
surrogates in MS patients treated with NTZ who either
switched to IFNB or continued on NTZ in a prospective,
one-year, randomized, rater-blinded study. The main result
of our study is that clinical and radiological disease activity
was larger in the de-escalating group, and that only 25% of
patients treated with IFNB were free from disease recurrence
(relapses, disability progression and nT2 brain lesions) after
one year. The primary endpoint (time to first on study re-
lapse) showed a clear trend in favor of continued NTZ treat-
ment, however, statistical significance was not reached
probably due to the small sample size. Moreover, given that
IFNB was started within 30 days of cessation of NTZ, there
may have been residual efficacy of NTZ for up to 3 months
in the IFNB group [8]. Also, relapses were not associated
with neutralizing antibodies against IFNB, which have been
associated with IFNB treatment failure.
Clinical results are supported by MRI findings showing
a statistically significant greater number of nT2L at month
6 and a coherent trend in favor of NTZ treatment for all
the remaining radiological endpoints. The higher number
of nT2L in the IFNB vs. the NTZ group at each time
point, and higher number of patients free of nT2L in the
NTZ treated arm indicate a higher efficacy of NTZ. This
is in line with previous reports, showing that radiological
reactivation peaks at months 4–7 following NTZ discon-
tinuation [3].
INFB, although not sufficient to protect from disease
recurrence, seems to exert a certain anti-inflammatory
activity after NTZ discontinuation: the three relapses oc-
curring in the IFNB group were mild and did not result
in sustained progression over 6 months. Also, there were
no cases of dramatic clinical worsening referable to im-
mune reconstitution inflammatory syndrome sometimes
described after NTZ discontinuation [3,4,9-11]. More-
over, as many as 77% (7/9) patients were free from re-
currence of clinical activity, and 25% from recurrence of
radiological activity over one year; the majority of pa-
tients had only one or two nT2L, and only three patients
showed three or more nT2 lesions.
The only randomized trial on NTZ de-escalation in-
cluding interferon beta as a comparator is the RESTORE
study [12], which evaluated the effect of a 24 week inter-
ruption in NTZ treatment comparing continued NTZ
treatment with placebo or with switching to GA, i.m inter-
feron beta 1a or methylprednisolone. The preliminary data
of the trial showed a high rate of recurrence of MRI and
clinical disease activity following NTZ discontinuation.
However, this study was limited by partial randomization
and imbalanced baseline characteristics of patients, and
was not powered to detect significant differences among
treatment groups. Our results are in line with the reduced
early reactivation risk following discontinuation of NTZ
observed with early GA treatment, which was recently de-
scribed by Rossi et al. [13] in a single-arm study limited by
the absence of a control arm. On the other hand, in two
small observational studies GA following NTZ cessation
was followed by severe recurrence of disease activity
[9,14]. Possible explanations of these apparently contras-
ting results may reflect the delayed onset of action of GA
[15] particularly considering that studies employed diffe-
rent wash out intervals before switching from NTZ to GA.
Of note, the ARR under de-escalation therapy with IFNB
was significantly lower than in the two years prior to the
run-in NTZ therapy. While this may reflect the natural
Table 1 Baseline characteristics of patients
IFNB (n=9) NTZ (n=10) p-value
Females, n (%)* 3 (33%) 6 (60%) 0.370
Age, [years] ‡ 39 (24–48) 43 (20–60) 0.460
Disease duration, [years] ‡ 12 (2–23) 10 (5–17) 0.712
Number of NTZ infusions
(run-in period) at baseline‡
21 (12–49) 25.5 (13–45) 0.661
Annualized relapse rate ‡
- during 2 years prior to
run-in period NTZ
1 (0.5-2.5) 1.3 (0.5-2.5) 0.661
- during run-in period NTZ 0 (0) 0(0–1.3) 0.497
EDSS ‡
- during 2 years prior to
run-in period NTZ
2( 1 –3.5) 2.5 (1–3.5) 0.616
- at randomization 3 (1.5-3.5) 3 (1.5-3.5) 0.714
Therapy before run-in therapy
with NTZ n (%) *
- no treatment 1 (11%) 2 (20%) 1.000
- Glatiramer acetate 1 (11%) 2 (20%) 1.000
- IFNbeta 1a im 1 (11%) 2 (20%) 1.000
- IFNbeta 1a sc 2 (22%) 3 (30%) 1.000
- IFNbeta 1b 4 (44%) 1 (10%) 0.141
*two-sided exact Fisher test, ‡ U-Mann–Whitney test; values are
median (range).
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duction effect by NTZ [3,5], it might also suggest that
IFNB could represent an alternative treatment for a se-
lected subgroup of patients de-escalating NTZ treatment.
In an attempt to define factors that would allow predicting
IFNB responders, we analyzed associations between on-
study disease activity with demographic, clinical and radio-
logical parameters prior to run-in NTZ therapy (data not
shown). However, we could not identify such biomarkers
yet, probably reflecting the small sample.
Our study has limitations. Firstly, the small sample size;
nonetheless, the study has a frequent MRI monitoring to
catch subclinical disease activity and increase sensitivity for
disease recurrence. Moreover, our sample is fully represen-
tative of the MS population treated with NTZ in southern
Switzerland as all patients receiving NTZ in this region are
treated at our Center. Clinical and radiological characteris-
tics of patients treated with NTZ at our Center who were
included or not in the study were similar (data not shown).
Sixty-three percent of our patients were free from any
radiological activity (i.e. Gd+L and nT2L lesions) under
NTZ treatment, analogous to the data reported for the first
year of the AFFIRM study [16]. Moreover, our patients ex-
perienced over 90% reduction of ARR under NTZ
treatment compared to the two years before NTZ initiation,
which is in line with the known efficacy of NTZ in active
MS patients [3]. Taken together, these data suggests that
our study population is similar to NTZ treated populations
reported in the literature. The absence of a placebo arm
represents the second limitation of the study but was ex-
pressly avoided for ethical considerations. Thirdly, patients
were not stratified according to anti JC virus antibodies
testing, which was not validated at the time when our study
was conducted.
Besides the frequent MRI monitoring and the highly sensi-
tive MRI metrics, the main strength of our study is the pro-
spective, randomized design. The study length can be
considered as appropriate given that NTZ fully clears from
the circulation in approximately two months (5 half-lives) and
CSF lymphocyte count remains suppressed up to 6 months
following the last dose [16]. Finally, our study was conducted
without third-party funding.
A larger trial is warranted to confirm present results
and possibly identify predictive markers to define that
segment of patients who is likely to be protected best
with de-escalation therapy with IFNB. This would mark
a significant advantage for a patient population that other-
wise runs a potentially increasing risk for PML with con-
tinued NTZ therapy.
Table 2 Study outcomes
IFNB (n=9) NTZ (n=10) p-value
Median time to first on study relapse (primary endpoint)* 103 days - 0.125
Number of relapses^ 3 0 0.447
Proportion of relapse free patients (number)° 78% (7) 100% (10) 0.206
Severity of relapses:
- EDSS score change, median (range) 0.5 (0.5 -1.5) - -
Number of patients with 3 months confirmed disability progression°:
(1 patient showed a disability progression of 1.5 points 1 month after an
attack occurred during month 11 of study)
00 1
Number of nT2L, median (range) ^
- at month 3 0.5 (0–2) 0 (0–1) 0.146
- at month 6 1.5 (0–9) 0 (0–2) 0.043
- at month 9 0.5 (0–6) 0 (0) 0.105
- at month 12 0 (0–12) 0 (0) 0.234
Number of Gd+L, median (range) ^
- at month 3 0 (0–1) 0 (0) 0.696
- at month 6 0 (0–5) 0 (0) 0.442
- at month 9 0 (0–1) 0 (0) 0.694
- at month 12 0 (0–2) 0 (0–1) 0.694
Adverse events
- number of infection, median (range) ^ 0 1 0.140
- proportion of patients with at least 1 infection ° 3 (33%) 7 (70%) 0.179
- number of patients with injection site reactions 4 n.a. -
* Log-rank test ; ^U-Mann Whitney test; ° two-sided exact Fisher test.
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http://www.biomedcentral.com/1471-2377/13/101Figure 2 Kaplan Meier survival curves representing the probability of being free of nT2L lesions throughout the study period under
de-escalation therapy with INFB or continued NTZ.
Figure 1 Mean number of new T2 lesions (nT2L) and gadolinium enhancing lesions (Gd+L) per patient at baseline and at month 3, 6, 9
and 12 of study (statistical analysis was performed with non parametric tests and reported in Results and Table 2).
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